Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Biohit Oyj
  6. News
  7. Summary
    BIOBV   FI0009005482

BIOHIT OYJ

(BIOBV)
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 09/23 07:00:05 am
2.03 EUR   0.00%
08/11BIOHIT OYJ : Group Half Year Financial Report 2021
AQ
08/11Biohit Oyj Reports Earnings Results for the Half Year Ended June 30, 2021
CI
08/11Biohit Provides Revenue Guidance for the Year 2021
CI
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biohit Oyj : Pńivi Siltala new CEO of Biohit Oyj

07/29/2021 | 02:01am EDT

Biohit Oyj stock exchange release 29th of July 2021 at 09.00 am local time (EET)

Changes in Management
 

The Board of Directors of Biohit Oyj has appointed MA Päivi Siltala the CEO of the company starting September 1, 2021. Siltala is joining Biohit from Johnson & Johnson where she has been Sales Director.

Siltala is an experienced biotechnology professional with a large international contact network. She also has a solid track record in managing business development and growth. Siltala has worked in Biohit 2008-2010 and thus knows the company and the technology, which speeds up operative integration.

"Siltala's experience in biotechnology and personal qualities and skills makes her excellent person to lead and develop Biohit business and operations to materialize company's commercial potential in the best possible way", says Eero Lehti, Chairman of the Board of Directors.

Beside Biohit and Johnson & Johnson, Siltala has worked in leading sales and business development positions at Pentax Medical and Cook Medical Endoscopy.

 

Additional information: 
Chairman of the Board of Directors Eero Lehti, Biohit Oyj
tel. +358 9 773 861

investor.relations@biohit.fi
www.biohithealthcare.com

 

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is "Innovating for Health" - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

https://news.cision.com/biohit-oyj/r/paivi-siltala-new-ceo-of-biohit-oyj,c3390202

(c) 2021 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
BIOHIT OYJ 0.00% 2.03 Delayed Quote.-18.15%
JOHNSON & JOHNSON -0.36% 163.93 Delayed Quote.4.16%
All news about BIOHIT OYJ
08/11BIOHIT OYJ : Group Half Year Financial Report 2021
AQ
08/11Biohit Oyj Reports Earnings Results for the Half Year Ended June 30, 2021
CI
08/11Biohit Provides Revenue Guidance for the Year 2021
CI
08/10BIOHIT OYJ : CE marked GastroPanel« quick test on the market
AQ
07/29BIOHIT OYJ : Appoints New CEO
MT
07/29BIOHIT OYJ : Päivi Siltala new CEO of Biohit Oyj
AQ
07/29Biohit Oyj Appoints MA Päivi Siltala as the CEO of the Company Starting September 1, 20..
CI
06/29BIOHIT OYJ : Constitutive meeting of Biohit Oyj's Board of Directors
AQ
06/29Biohit Oyj Elects Eero Lehti as the Chairman of the Board of Directors
CI
06/28BIOHIT OYJ : Changes in Management Team
AQ
More news
Financials
Sales 2020 7,12 M 8,35 M 8,35 M
Net income 2020 -3,31 M -3,88 M -3,88 M
Net cash 2020 5,70 M 6,68 M 6,68 M
P/E ratio 2020 -11,3x
Yield 2020 -
Capitalization 30,5 M 35,9 M 35,8 M
EV / Sales 2019 4,13x
EV / Sales 2020 4,44x
Nbr of Employees 48
Free-Float 42,6%
Chart BIOHIT OYJ
Duration : Period :
Biohit Oyj Technical Analysis Chart | BIOBV | FI0009005482 | MarketScreener
Technical analysis trends BIOHIT OYJ
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Managers and Directors
Pńivi Siltala Chief Executive Officer
Jussi Hahtela Chief Financial Officer
Eero Heikki Lehti Chairman
Minna Mńki Director-Research & Development
Timo Joensuu Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOHIT OYJ-18.15%36
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972